AI filing briefs · archive

8-K filings in July 2026, explained

1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).

2 of 1,916 briefs match

newest first · times in ET

BETABETA Technologies, Inc. Jul 22, 4:50 PM ET

BETA Technologies: Government Security Control Agreement Terminated After QIA Board Exit

Neutral legal/regulatory Written later 1.02

BETA Technologies received notice on July 14, 2026 that the Defense Counterintelligence and Security Agency ended the Security Control Agreement dated June 15, 2025, which had mitigated foreign ownership and influence concerns tied to QIA Industrials Holding. DCSA determined the agreement was no longer necessary because QIA no longer has a seat on the Company's Board of Directors.

Security Control Agreement dated June 15, 2025 terminated, per DCSA notice received July 14, 2026
Agreement parties: QIA Industrials Holding, LLC, BETA Technologies, and the U.S. Department of Defense
Reason given: QIA no longer has board representation at the Company

Read the filing on SEC.gov ↗

MNPRMonopar Therapeutics Jul 22, 8:00 AM ET

Monopar Starts Rolling NDA Submission for ALXN1840 in Wilson Disease

Neutral legal/regulatory Written later 7.01

Monopar Therapeutics said it has begun a rolling submission of a New Drug Application to the FDA for ALXN1840 (tiomolibdate choline) for Wilson disease, and has submitted its first completed sections. The filing is a regulatory milestone; approval is not assured, and the company says the drug could receive a pediatric Priority Review Voucher if approved.

Monopar has initiated a rolling NDA submission for ALXN1840 with the FDA and has submitted the first completed sections.
The FDA authorized the rolling submission, which lets completed sections be reviewed while remaining sections are finalized.
ALXN1840 received Rare Pediatric Disease designation from the FDA in June 2026, which could allow a pediatric Priority Review Voucher at approval.

Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.